BioNTech SE (Nasdaq:BNTX) will partner with Matinas BioPharma (NYSE AMER:MTNB) to develop mRNA formats that use Matinas’ proprietary lipid nanocrystal (LNC) platform technology that could enable oral delivery. The two companies will partner on formulation, optimization and in vitro testing. BioNTech CEO Dr. Ugur Sahin said that the partnership could lead to the development of…